Biodegradable starch microspheres (DSM) is Magle's area of key expertise and focus. Customised variants of DSM, each with their unique set of properties, are currently available within the therapeutic fields of chemoembolisation and hemostasis respectively.
The people working at Magle Life Sciences share an extensive knowledge of polysaccharide technology and chemistry, for the development and manufacturing of specialty pharmaceuticals and healthcare products.
Magle welcomes new development initiatives from industrial partners where we are capable of developing ideas from conception through to full scale manufacturing under pharmaceutical GMP conditions. By employing process oriented development, we safeguard a fast and seemless route to future production.
Company Milestones
2001 Acquired 25% stake in PKC A/S
2001 DSM-A supply agrement with Medafor, Inc
2002 Initiated self financed development of a new oral pharmaceutical delivery system
2004 DSM-S supply agreement with Pfizer, Inc
2005 Launched Arista® hemostat in northern Europe
2006 Launched Phadebas® Amylase Test
2006 Acquired Debrisan® wound care technology
2007 Launched Phadebas Forensic
2008 Partnering agreement for Magle's proprietary oral drug delivery system
2008 Collaboration with partner for the development of DSM-C
2009 Acquired Spherex® (outside JP) from Pfizer
2009 ISO 13485 certified
2010 Acquired a 7% stake in Medafor, Inc
Key people
Hans Henrik Lidgard, Jur. Dr., Chairman
Eddie Thordarson, Ph.D., CEO
Fredrik Ouchterlony, M.Sc., CFO
Peter Fyhr, M.Sc.(Pharm.) Ph.D., CSO
Patrik Tiede, M.Sc., Lab and Production Manager
Birgitta Tennhammar Ekman, M.Sc.(Pharm.) Ph.D., QA Manager
Board
Hans Henrik Lidgard (chair)
Ingemar Jonsson
Anthony Simon
Sven-Christer Nilsson
Malin Malmsjö
Scientific advisors
Leif Lidén
Dr. Leif Håkansson
Dr. Bo Ekman
Dr. Gustaf Plym Forsell
Dr. Malin Malmsjö
Contact
Magle AB
Magle Stora Kyrkogata 6
S-223 50 Lund
SWEDEN
Phone +46 46 157708
Fax +46 46 157716
info@magle.se
